Fig. 6: Synergistic effect of AlloCAR70-NKT cells with HMA in the treatment of CD70-negative AML using a HL60-FG xenograft mouse model. | Leukemia

Fig. 6: Synergistic effect of AlloCAR70-NKT cells with HMA in the treatment of CD70-negative AML using a HL60-FG xenograft mouse model.

From: Synergizing hypomethylating agents with off-the-shelf CD70-targeted chimeric antigen receptor-engineered natural killer T cells for the treatment of acute myeloid leukemia

Fig. 6: Synergistic effect of AlloCAR70-NKT cells with HMA in the treatment of CD70-negative AML using a HL60-FG xenograft mouse model.

A Experimental design to study the synergistic effect of AlloCAR70-NKT cells with Decitabine in vivo. A human CD70- AML cell line HL60-FG was utilized. B BLI images showing the presence of HL60-FG tumor cells in experimental mice over time. C Quantification of (B) (n = 5). D Kaplan–Meier survival curves (n = 5). E ELISA analyses of human IFN-γ and TNF-α levels in serum collected from experimental mice on day 18. F FACS analyses of the percentage of AlloCAR70-NKT cells among total live mononuclear cells in mouse tissues on day 25 (n = 5). Representative of 3 experiments. Data are presented as the mean ± SEM. ns not significant, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, by Student’s t test (F), one-way ANOVA (E), or log rank (Mantel-Cox) test adjusted for multiple comparisons (D).

Back to article page